RecruitingNot Applicable

Optimizing the Diagnosis of Pneumocystis in Immunocompromised Patients

France240 participantsStarted 2025-07-08

Plain-language summary

Evaluate new diagnostic methods using qPCR on non-invasive samples, compared with reference techniques for the positive diagnosis of pneumocystis (PcP) in immunocompromised patients

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * adult patients with suspected pneumocystis * with an indication for bronchial fibroscopy for BAL or induced sputum * no opposition to the research from the adult patient or his or her next of kin research for patients unable to express their non-opposition Exclusion Criteria: * Pneumocystis treated for more than 72 hours * pregnancy/breast-feeding * adult patients deprived of liberty, protected

What they're measuring

Pearson correlation coefficient

Timeframe: At inclusion

Trial details

NCT IDNCT06890078

SponsorAssistance Publique - Hôpitaux de Paris

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2027-07-08

Contact for this trial

Agathe Vigouroux, MD

0142494683 agathelaure.vigouroux@aphp.fr

View on ClinicalTrials.gov More Pneumocystis trials